A national population-based study of cannabis use and correlates among U.S. veterans prescribed opioids in primary care

dc.contributor.authorZaman, Tauheed
dc.contributor.authorBravata, Dawn M.
dc.contributor.authorByers, Amy L.
dc.contributor.authorKrebs, Erin E.
dc.contributor.authorLeonard, Samuel J.
dc.contributor.authorSandbrink, Friedhelm
dc.contributor.authorBarker, Wylie
dc.contributor.authorKeyhani, Salomeh
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2023-11-20T12:20:23Z
dc.date.available2023-11-20T12:20:23Z
dc.date.issued2023-03-17
dc.description.abstractBackground: Cannabis is marketed as a treatment for pain. There is limited data on the prevalence of cannabis use and its correlates among Veterans prescribed opioids. Objective: To examine the prevalence and correlates of cannabis use among Veterans prescribed opioids. Design: Cross-sectional study. Participants: Veterans with a urine drug test (UDT) from Primary Care 2014-2018, in 50 states, Washington, D.C., and Puerto Rico. A total of 1,182,779 patients were identified with an opioid prescription within 90 days prior to UDT. Main measures: Annual prevalence of cannabis positive UDT by state. We used multivariable logistic regression to assess associations of demographic factors, mental health conditions, substance use disorders, and pain diagnoses with cannabis positive UDT. Results: Annual prevalence of cannabis positive UDT ranged from 8.5% to 9.7% during the study period, and in 2018 was 18.15% in Washington, D.C. and 10 states with legalized medical and recreational cannabis, 6.1% in Puerto Rico and 25 states with legalized medical cannabis, and 4.5% in non-legal states. Younger age, male sex, being unmarried, and marginal housing were associated with use (p < 0.001). Post-traumatic stress disorder (adjusted odds ratio [AOR] 1.17; 95% confidence interval [CI] 1.13-1.22, p < 0.001), opioid use disorder (AOR 1.14; CI 1.07-1.22, p < 0.001), alcohol use disorder or positive AUDIT-C (AOR 1.34; 95% CI 1.28-1.39, p < 0.001), smoking (AOR 2.58; 95% CI 2.49-2.66, p < 0.001), and other drug use disorders (AOR 1.15; 95% CI 1.03-1.29, p = 0.02) were associated with cannabis use. Positive UDT for amphetamines AOR 1.41; 95% CI 1.26-1.58, p < 0.001), benzodiazepines (AOR 1.41; 95% CI 1.31-1.51, p < 0.001) and cocaine (AOR 2.04; 95% CI 1.75-2.36, p < 0.001) were associated with cannabis positive UDT. Conclusions: Cannabis use among Veterans prescribed opioids varied by state and by legalization status. Veterans with PTSD and substance use disorders were more likely to have cannabis positive UDT. Opioid-prescribed Veterans using cannabis may benefit from screening for these conditions, referral to treatment, and attention to opioid safety.
dc.eprint.versionFinal published version
dc.identifier.citationZaman T, Bravata DM, Byers AL, et al. A national population-based study of cannabis use and correlates among U.S. veterans prescribed opioids in primary care. BMC Psychiatry. 2023;23(1):177. Published 2023 Mar 17. doi:10.1186/s12888-023-04648-5
dc.identifier.urihttps://hdl.handle.net/1805/37152
dc.language.isoen_US
dc.publisherBMC
dc.relation.isversionof10.1186/s12888-023-04648-5
dc.relation.journalBMC Psychiatry
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePMC
dc.subjectCannabis
dc.subjectOpiates
dc.subjectOpioid therapy
dc.subjectVeterans
dc.titleA national population-based study of cannabis use and correlates among U.S. veterans prescribed opioids in primary care
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
12888_2023_Article_4648.pdf
Size:
1.44 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: